Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Cancer drugs funding

Drug firms must price cancer drugs fairly, says charity

‘Inflated’ prices set by drug companies for breast cancer treatments are creating a barrier that no regulatory system can overcome, a cancer charity argues.

Breakthrough Breast Cancer has raised its concerns to the government about the ever-increasing price of new oncology medicines.

A £280m annual Cancer Drugs Fund (CDF) has been set up in England to pay for new anti-cancer drugs not recommended by National Institute for Health and Care Excellence (NICE). But, this funding is only guaranteed until March 2016 and the specialist commissioning budget, which finances the fund, is currently struggling to meet demand.

At an event at the House of Commons on 29 October 2014 — part of the charity’s ‘Demand a Fair Price’ campaign — it said it wants a commitment from all political parties to extend the CDF in England until the end of the next Parliament (2020). It also wants all parties to commit to finding a long-term, UK-wide solution to a lack of routine access to life-extending drugs.

It also called for the Welsh and Northern Ireland assemblies to introduce a similar system to the CDF to ensure that patients get access to the anticancer drugs.

The Association of the British Pharmaceutical Industry, which represents pharmaceutical companies, says the CDF improves access, but calls for a longer-term solution, primarily for the reform of NICE to allow greater uptake.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067021

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and British National Formulary for Children

    BNF and British National Formulary for Children

    Now available as a 1 year print subscription to both the BNF and British National Formulary for Children, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and British National Formulary for Children

    BNF and British National Formulary for Children

    Now available as a 2 year print subscription to both the BNF and British National Formulary for Children, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.